Search

PPARalpha and PPARgamma activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective

Mesothelioma is a cancer that typically originates in the pleura of the lungs. It rapidly invades the surrounding tissues, causing pain and shortness of breath. We compared cell lines injected either subcutaneously or intrapleurally and found that only the latter resulted in invasive and rapid growth.

Increasing diversity within the Global Lung Function Initiative

The Global Lung Function Initiative has worked to develop all‐age, multi‐ethnic reference equations for the major clinical lung function tests

The potential of phage therapy in cystic fibrosis

This review summarises the phage-microbe-human lung interactions in CF that must be addressed to successfully develop and deliver phage to CF airways

The global lung function initiative (GLI) network: Bringing the world’s respiratory reference values together

The Global Lung Function Initiative (GLI) Network has become the largest resource for reference values for routine lung function testing ever assembled.

Key paediatric messages from the 2016 european respiratory society international congress

In this article, the Group Chairs of the Paediatric Assembly of the European Respiratory Society (ERS) highlight some of the most interesting abstracts presented at the 2016 ERS International Congress, which was held in London.

Key paediatric messages from the 2016 European respiratory society international congress

Highlight of some of the most interesting abstracts presented at the 2016 ERS International Congress, which was held in London

Developing clinical predictors of disease progression in children with neuromuscular disorders to prevent future respiratory failure

Graham Hall BAppSci PhD CRFS FANZSRS FThorSoc FERS Honorary Research Associate Honorary Research Associate Professor Graham Hall is an

Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

A Phase II Randomized, Controlled, Observer-Blinded Study, Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine When Administered to Healthy Toddlers

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical